ClinicalTrials.gg
CompletedNCT00385255Updated Jun 10, 2019Results posted

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

A Phase 3 interventional study of Fluarix® and Boostrix® in Acellular Pertussis, Diphtheria and Tetanus, sponsored by GlaxoSmithKline. Completed at 12 sites in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,726
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing boostrix in Diphtheria — 3 open to participants now, 3 under way, none of them phase 3. Boostrix · Diphtheria.

Enrollment
2nd of 21
1,726 · median 460
Started
2006
with 3 others
Phase 3
10 of 21
none open now
Registered
4th of 21
by date
Lead sponsor
17 of 21
GlaxoSmithKline

Among the 21 studies testing boostrix in Diphtheria, this one is the 2nd largest by enrollment, is one of 4 that started in 2006, is one of 10 in phase 3, and was the 4th registered.

Diphtheria

267 studies on the registry are indexed under Diphtheria; 17 are open to participants now.

Browse Diphtheria studies →

Open to participants now

3 of the 21 studies testing boostrix in Diphtheria are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing boostrix in Diphtheria, or all of them as a file.
02

Study summary

The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.

03

Conditions studied

  • Acellular Pertussis
  • Diphtheria
  • Tetanus

Keywords

  • Immunogenicity,
  • Influenza
  • Co-administration,
  • Tdap,
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female adults aged between 19 to 64 years, inclusive for the primary cohort), or aged 65 years or older (for the exploratory cohort), at the time of vaccination.

Exclusion criteria

Exclusion Criteria:

  • Administration of an influenza vaccine within six months prior to study entry
  • Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.
  • Administration of a Tdap vaccine at any time prior to study entry.
  • Administration of any or non-registered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period.
  • History of diphtheria and/or tetanus and/or pertussis disease.
  • History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or influenza vaccine or any component of the study vaccines.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,726 participants (actual)

Study arms

  • Experimental
    BOOSTRIX+FLUARIX GROUP

    Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.

    Biological: Fluarix® · Biological: Boostrix®

  • Experimental
    FLUARIX BOOSTRIX GROUP

    Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.

    Biological: Fluarix® · Biological: Boostrix®

Interventions

  • BiologicalFluarix®

    GSK Biologicals' inactivated influenza split virus vaccine.

  • BiologicalBoostrix®

    GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens

    A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL), respectively.

    Time frame: At Month 1 post-Boostrix® vaccination

  2. Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value

    The assay cut-off value was ≥ 1.0 IU/mL, as assessed by enzyme-linked immunosorbent assay (ELISA).

    Time frame: At Month 1 post-Boostrix® vaccination

  3. Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens

    Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

    Time frame: At Month 1 post-Boostrix® vaccination

  4. Number of Subjects With Serum Haemagglutinin Inhibition (HI) Titers Against 3 Strains of Influenza

    The antibody titer cut-off value for the 3 influenza strains assessed (H1N1, H3N2 and B) was ≥ 1:40.

    Time frame: At Month 1 post-Fluarix® vaccination

  5. Number of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B

    Seroconversion for HI antibodies is defined as: For initially seronegative subjects: post-vaccination antibody titer ≥ 1:40 at Month 1 post-Boostrix® vaccination; For initially seropositive subjects: antibody titer at Month 1≥ 4 fold the pre-vaccination antibody titer.

    Time frame: At Month 1 post-Fluarix® vaccination

Secondary outcomes

  1. Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value

    A seropositive subject was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value of 1.0 IU/mL.

    Time frame: At Month 1 post-Boostrix® vaccination

  2. Antibody Concentrations for Diphteria Toxoid (D) and Tetanus Toxoid (T)

    Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL).

    Time frame: At Day 0 and Month 1 post-Boostrix® vaccination

  3. Antibody Concentrations for Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN)

    Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

    Time frame: At Day 0 and Month 1 post-Boostrix® vaccination

  4. Number of Subjects With Booster Response Against Diphteria Toxoid (D) and Tetanus Toxoid (T) Antigens

    Booster responses for anti-D and anti-T antibodies are defined as: For initially seronegative subjects \[pre-vaccination concentration below (\<) cut-off 0.1 IU/mL\]: antibody concentrations at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL), one month after vaccination with Boostrix®; For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with Boostrix®.

    Time frame: At Month 1 post-Boostrix® vaccination

  5. Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens

    Booster responses for anti-PT, anti-FHA and anti-PRN are defined as: For initially seronegative subjects (pre-vaccination concentration \< cut-off of 5 EL.U/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration ≥ 20 EL.U/mL), one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with Boostrix®.

    Time frame: At Month 1 post-Boostrix® vaccination

  6. Anti-H1N1, Anti-H3N2 and Anti-B Antibody Titers

    Anti-H1N1, anti-H3N2 and anti-B antibody titers are presented as geometric mean titers (GMTs).

    Time frame: At Month 1 post-Fluarix® vaccination

  7. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.

    Time frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months

  8. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain, muscle aches and shivering. Any = occurrence of the symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.

    Time frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months

  9. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day period (Day 0-30) following each vaccination, up to 2 months

  10. Number of Subjects With Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Throughout the whole study period (from Day 0 to Month 2)

07

Results

Posted Sep 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneBoostrix+Fluarix GroupFluarix Boostrix Group
Started860858
≥ 65 years of age (yoa) cohort112109
19-64 years of age (yoa) cohort748749
Completed839785
Not completed2173
Withdrew: Serious adverse event12
Withdrew: Protocol violation04
Withdrew: Withdrawal by subject08
Withdrew: Migrated/moved from study area01
Withdrew: Lost to follow-up2058

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens

A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL), respectively.

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-D6776149379
Anti-T70065310595
Statistical analysis
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: 1.06 · 95% CI -1.36 to 3.56
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: -1.67 · 95% CI -2.96 to -0.74
PrimaryNumber of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value

The assay cut-off value was ≥ 1.0 IU/mL, as assessed by enzyme-linked immunosorbent assay (ELISA).

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value6876219484
Statistical analysis
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: 1.40 · 95% CI -0.77 to 3.68
PrimaryAntibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens

Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
EL.U/mLBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-PT57.5 (53.1 to 62.3)76.9 (71.1 to 83.2)51.2 (40.8 to 64.2)59.3 (47.0 to 74.8)
Anti-FHA467.6 (434.9 to 502.8)663.3 (613.3 to 717.4)502.5 (409.5 to 616.7)669.6 (539.1 to 831.8)
Anti-PRN234.9 (208.7 to 264.3)343.6 (302.5 to 390.1)87.9 (60.1 to 128.5)97.0 (68.1 to 138.4)
Statistical analysis
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · ANCOVA · Adjusted gmc ratio: 0.74 · 95% CI 0.67 to 0.82
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · ANCOVA · Adjusted gmc ratio: 0.71 · 95% CI 0.64 to 0.79
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · ANCOVA · Adjusted gmc ratio: 0.70 · 95% CI 0.60 to 0.81
PrimaryNumber of Subjects With Serum Haemagglutinin Inhibition (HI) Titers Against 3 Strains of Influenza

The antibody titer cut-off value for the 3 influenza strains assessed (H1N1, H3N2 and B) was ≥ 1:40.

Time frame:
At Month 1 post-Fluarix® vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Serum Haemagglutinin Inhibition (HI) Titers Against 3 Strains of Influenza
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-H1N16696439288
Anti-H3N269466310495
Anti-B685654107101
Statistical analysis
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: -1.17 · 95% CI -3.58 to 1.23
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: -0.61 · 95% CI -2.22 to 0.96
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in percentage: -0.55 · 95% CI -2.52 to 1.42
PrimaryNumber of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B

Seroconversion for HI antibodies is defined as: For initially seronegative subjects: post-vaccination antibody titer ≥ 1:40 at Month 1 post-Boostrix® vaccination; For initially seropositive subjects: antibody titer at Month 1≥ 4 fold the pre-vaccination antibody titer.

Time frame:
At Month 1 post-Fluarix® vaccination
Reported as:
Count of participants · Participants
Number of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-H1N14143773732
Anti-H3N25604947264
Anti-B4634254143
Statistical analysis
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in seroconversion rate: 2.37 · 95% CI -2.84 to 7.58
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in seroconversion rate: 5.58 · 95% CI 1.10 to 10.07
  • Boostrix+Fluarix 19-64 YOA Group vs Fluarix Boostrix 19-64 YOA Group · Difference in seroconversion rate: 2.15 · 95% CI -2.90 to 7.20
SecondaryNumber of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value

A seropositive subject was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value of 1.0 IU/mL.

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Count of participants · Participants
Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value5795285549
SecondaryAntibody Concentrations for Diphteria Toxoid (D) and Tetanus Toxoid (T)

Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL).

Time frame:
At Day 0 and Month 1 post-Boostrix® vaccination
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Diphteria Toxoid (D) and Tetanus Toxoid (T)
IU/mLBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-D, Day 00.4 (0.4 to 0.4)0.4 (0.3 to 0.4)0.2 (0.1 to 0.2)0.2 (0.2 to 0.3)
Anti-D, Month 13.1 (2.8 to 3.5)3.4 (3.0 to 3.8)1.0 (0.7 to 1.4)1.0 (0.6 to 1.4)
Anti-T, Day 01.5 (1.4 to 1.7)1.5 (1.3 to 1.6)0.5 (0.4 to 0.7)0.6 (0.4 to 0.8)
Anti-T, Month 16.5 (6.0 to 7.0)7.6 (7.0 to 8.2)3.4 (2.7 to 4.3)3.6 (2.6 to 5.0)
SecondaryAntibody Concentrations for Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN)

Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

Time frame:
At Day 0 and Month 1 post-Boostrix® vaccination
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations for Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN)
EL.U/mLBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-PT, Day 06.4 (5.9 to 6.9)6.5 (6.0 to 7.1)8.0 (6.4 to 10.0)8.0 (6.4 to 9.9)
Anti-PT, Month 157.5 (53.1 to 62.3)76.9 (71.1 to 83.2)51.2 (40.8 to 64.2)59.3 (47.0 to 74.8)
Anti-FHA, Day 036.6 (33.7 to 39.9)36.2 (33.2 to 39.5)54.5 (43.2 to 68.7)59.0 (46.5 to 75.0)
Anti-FHA, Month 1467.6 (434.9 to 502.8)663.3 (613.3 to 717.4)502.5 (409.5 to 616.7)669.6 (539.1 to 831.8)
Anti-PRN, Day 012.6 (11.4 to 13.9)12.9 (11.7 to 14.3)7.5 (5.9 to 9.4)6.4 (5.0 to 8.2)
Anti-PRN, Month 1234.9 (208.7 to 264.3)343.6 (302.5 to 390.1)87.9 (60.1 to 128.5)97.0 (68.1 to 138.4)
SecondaryNumber of Subjects With Booster Response Against Diphteria Toxoid (D) and Tetanus Toxoid (T) Antigens

Booster responses for anti-D and anti-T antibodies are defined as: For initially seronegative subjects \[pre-vaccination concentration below (\<) cut-off 0.1 IU/mL\]: antibody concentrations at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL), one month after vaccination with Boostrix®; For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with Boostrix®.

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Booster Response Against Diphteria Toxoid (D) and Tetanus Toxoid (T) Antigens
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-D4874596148
Anti-T2933206263
SecondaryNumber of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens

Booster responses for anti-PT, anti-FHA and anti-PRN are defined as: For initially seronegative subjects (pre-vaccination concentration \< cut-off of 5 EL.U/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration ≥ 20 EL.U/mL), one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with Boostrix®.

Time frame:
At Month 1 post-Boostrix® vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-PT5145307168
Anti-FHA6516219491
Anti-PRN6305897977
SecondaryAnti-H1N1, Anti-H3N2 and Anti-B Antibody Titers

Anti-H1N1, anti-H3N2 and anti-B antibody titers are presented as geometric mean titers (GMTs).

Time frame:
At Month 1 post-Fluarix® vaccination
Reported as:
Geometric mean · Titers
Anti-H1N1, Anti-H3N2 and Anti-B Antibody Titers
TitersBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Anti-H1N1189.1 (171.7 to 208.3)181.6 (165.5 to 199.3)79.9 (65.0 to 98.3)89.3 (72.8 to 109.5)
Anti-H3N2368.7 (337.9 to 402.3)337.3 (309.2 to 367.9)333.6 (267.8 to 415.5)276.8 (212.4 to 360.8)
Anti-B210.1 (194.4 to 227.0)222.8 (205.9 to 241.1)221.2 (184.3 to 265.4)214.3 (175.4 to 261.8)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.

Time frame:
During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Any Pain, Dose 14673154125
Grade 3 Pain, Dose 128701
Any Redness, Dose 11801482315
Grade 3 Redness, Dose 14532
Any Swelling, Dose 1179931811
Grade 3 Swelling, Dose 112731
Any Pain, Dose 20327030
Grade 3 Pain, Dose 20903
Any Redness, Dose 20124016
Grade 3 Redness, Dose 20302
Any Swelling, Dose 2010609
Grade 3 Swelling, Dose 20600
Any Pain, Across doses4674294144
Grade 3 Pain, Across doses281504
Any Redness, Across doses1802072320
Grade 3 Redness, Across doses4834
Any Swelling, Across doses1791601817
Grade 3 Swelling, Across doses121231
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain, muscle aches and shivering. Any = occurrence of the symptom regardless of intensity grade or relationship to the study vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.

Time frame:
During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Any Fatigue, Dose 12201652018
Grade 3 Fatigue, Dose 1221501
Related Fatigue, Dose 11441031512
Any Fever, Dose 1545243
Grade 3 Fever, Dose 11000
Related Fever, Dose 1282832
Any Gastrointestinal, Dose 11211011812
Grade 3 Gastrointestinal, Dose 1161121
Related Gastrointestinal, Dose 16855126
Any Headache, Dose 12251971717
Grade 3 Headache, Dose 1242521
Related Headache, Dose 11431181213
Any Joint pain, Dose 1137871413
Grade 3 Joint pain, Dose 1101000
Related Joint pain, Dose 19756812
Any Muscle aches, Dose 12661932618
Grade 3 Muscle aches, Dose 1271520
Related Muscle aches, Dose 11941311617
Any Shivering, Dose 1704454
Grade 3 Shivering, Dose 18500
Related Shivering, Dose 1423043
Any Fatigue, Dose 2011506
Grade 3 Fatigue, Dose 201800
Related Fatigue, Dose 208305
Any Fever, Dose 203804
Grade 3 Fever, Dose 20100
Related Fever, Dose 202302
Any Gastrointestinal, Dose 205503
Grade 3 Gastrointestinal, Dose 20601
Related Gastrointestinal, Dose 202901
Any Headache, Dose 2013208
Grade 3 Headache, Dose 201200
Related Headache, Dose 208707
Any Joint pain, Dose 207507
Grade 3 Joint pain, Dose 201400
Related Joint pain, Dose 205207
Any Muscle aches, Dose 20183014
Grade 3 Muscle aches, Dose 202100
Related Muscle aches, Dose 20150013
Any Shivering, Dose 204802
Grade 3 Shivering, Dose 20700
Related Shivering, Dose 203402
Any Fatigue, Across doses2202182022
Grade 3 Fatigue, Across doses223001
Related Fatigue, Across doses1441491516
Any Fever, Across doses548047
Grade 3 Fever, Across doses1100
Related Fever, Across doses284734
Any Gastrointestinal, Across doses1211321813
Grade 3 Gastrointestinal, Across doses161622
Related Gastrointestinal, Across doses6873127
Any Headache, Across doses2252511722
Grade 3 Headache, Across doses243321
Related Headache, Across doses1431631219
Any Joint pain, Across doses1371351418
Grade 3 Joint pain, Across doses102300
Related Joint pain, Across doses9789817
Any Muscle aches, Across doses2662872626
Grade 3 Muscle aches, Across doses273420
Related Muscle aches, Across doses1942241625
Any Shivering, Across doses708055
Grade 3 Shivering, Across doses81000
Related Shivering, Across doses425644
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day period (Day 0-30) following each vaccination, up to 2 months
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs)
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Number of Subjects With Any Unsolicited Adverse Events (AEs)1612052221
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Throughout the whole study period (from Day 0 to Month 2)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsBoostrix+Fluarix 19-64 YOA GroupFluarix Boostrix 19-64 YOA GroupBoostrix+Fluarix ≥ 65 YOA GroupFluarix Boostrix ≥ 65 YOA Group
Number of Subjects With Serious Adverse Events (SAEs)2710

Adverse events

Collected over Solicited local and general symptoms: during the 15-day (Day 0-14) period following each vaccination; Unsolicited AEs: during the 31-day period (Day 0-30) following each vaccination; SAEs: throughout the whole study period (from Day 0 to Month 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix+Fluarix Group0/860 (0%)3/860 (0.3%)640/860 (74.4%)
Fluarix Boostrix Group0/858 (0%)7/858 (0.8%)619/858 (72.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBoostrix+Fluarix GroupFluarix Boostrix Group
Chest painGeneral disorders0/8602/858
HeadacheNervous system disorders0/8602/858
AnaemiaBlood and lymphatic system disorders0/8601/858
Gastric ulcerGastrointestinal disorders0/8601/858
VomitingGastrointestinal disorders0/8601/858
PneumoniaInfections and infestations0/8601/858
Diabetic ketoacidosisMetabolism and nutrition disorders0/8601/858
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/8601/858
DyspnoeaRespiratory, thoracic and mediastinal disorders0/8601/858
UrosepsisInfections and infestations1/8600/858
Most frequent other events
Most frequent other events
EventBoostrix+Fluarix GroupFluarix Boostrix Group
PainGeneral disorders509/860473/858
MyalgiaMusculoskeletal and connective tissue disorders294/860313/858
HeadacheNervous system disorders244/860276/858
FatigueGeneral disorders240/860240/858
ErythemaSkin and subcutaneous tissue disorders203/860227/858
SwellingGeneral disorders198/860177/858
ArthralgiaMusculoskeletal and connective tissue disorders151/860156/858
Gastrointestinal disorderGastrointestinal disorders139/860145/858
PyrexiaGeneral disorders59/86088/858
ChillsGeneral disorders76/86086/858

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Boostrix+Fluarix GroupFluarix Boostrix GroupTotal
Mean48.95 ± 14.7449.29 ± 14.5849.12 ± 14.66
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix+Fluarix GroupFluarix Boostrix GroupTotal
Female5274811008
Male333377710
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Boostrix+Fluarix GroupFluarix Boostrix GroupTotal
Geographic ancestry — African heritage/African American6982151
Geographic ancestry — American Indian or Alaskan native202
Geographic ancestry — Asian-Central/South Asian heritage011
Geographic ancestry — Asian-East Asian heritage123
Geographic ancestry — Asian-Japanese heritage123
Geographic ancestry — Asian-South East Asian heritage347
Geographic ancestry — Native Hawaiian or other Pacific Islander101
Geographic ancestry — White-Arabic/North African heritage7411
Geographic ancestry — White-Caucasian/European heritage7597471506
Geographic ancestry — Not specified171633
08

Study locations

12 sites
  • GSK Investigational Site
    Huntsville, Alabama 35802, United States
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Phoenix, Arizona 85014, United States
  • GSK Investigational Site
    Inverness, Florida 34452, United States
  • GSK Investigational Site
    Melbourne, Florida 32935, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    Peoria, Illinois 61602, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15217, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15220, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Houston, Texas 77024, United States
09

References and documents

Publications

  • Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009 Dec;5(12):858-66. doi: 10.4161/hv.9961. Epub 2009 Dec 31. PubMed 19838080 ↗
  • Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix((R))): results of two randomized trials. Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31. PubMed 22212127 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2006 to primary completion in Feb 2007, 4 months.

Results were first posted in Sep 2018, 11 years 6 months after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 4 months is below that.

Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2006
First posted
Oct 9, 2006
StartActual
Oct 23, 2006
Primary completionActual
Feb 28, 2007
CompletionActual
Feb 28, 2007
Results first posted
Sep 17, 2018
Last update
Jun 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00385255
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 9, 2006
Start date
Oct 23, 2006
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007
Results posted
Sep 17, 2018
Last update
Jun 10, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluarix · Boostrix

Start the discussion